‘Strikingly better’: Co-antibody combination tops golimumab, guselkumab in refractory IBD

benzinga.com·May 19, 2026 · 2 g fa

ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies - ImmunityBio (NASDAQ:IBRX)

fiercepharma.com·May 19, 2026 · 2 g fa

UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi

medpagetoday.com·May 17, 2026 · 4 g fa

Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment

morningstar.com·May 22, 2026 · 8 h fa

/C O R R E C T I O N — Innovent Biologics/

morningstar.com·May 22, 2026 · 13 h fa

2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

morningstar.com·May 22, 2026 · 13 h fa

2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety

endpoints.news·May 21, 2026 · 16 h fa

Merck partner Kelun outlines Phase 3 lung cancer success in China study

morningstar.com·May 20, 2026 · 2 g fa

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

biopharmadive.com·May 18, 2026 · 4 g fa

Regeneron immunotherapy combo comes up short in melanoma trial

endpoints.news·May 21, 2026 · 16 h fa

New data show VEGF bispecifics could compete with Summit, Akeso drug